CoChat
Sign Up
Cited by 75Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

APOE and Alzheimer’s Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction

Open access
Brandon, Jason A., Farmer, Brandon C., Williams, Holden C., Johnson, Lance A.·2018·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2018.00180PMC PMC6010552
Open this paper in CoChat — free accountOpen PDF

Abstract

Apolipoprotein E4 is the strongest genetic risk factor for late onset Alzheimer’s Disease (AD) and is associated with impairments in cerebral metabolism and cerebrovascular function. A substantial body of literature now points to E4 as a driver of multiple impairments seen in AD, including blunted brain insulin signaling, mismanagement of brain cholesterol and fatty acids, reductions in blood brain barrier integrity, and decreased cerebral glucose uptake. Various neuroimaging techniques, in particular PET and MRI, have been instrumental in characterizing these metabolic and vascular deficits associated with this important AD risk factor. In the current mini-review, we summarize the known effects of APOE on cerebral metabolism and cerebrovascular function, with a special emphasis on recent findings via neuroimaging approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2018.00180

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE4 is associated with increased Aβ deposition, but its influence on metabolic pathways may contribute to AD risk independently of Aβ.

    “As such, APOE4 is associated with increased Aβ deposition but accumulating evidence suggests that its influence on metabolic pathways may contribute to disease risk independently of Aβ [3][4][5][6][7] .”

    From APOE4-drives brain bioenergetic shifts independent of Alzheimer’s disease pathology (2026) · cites this paper as [6]

    The section on cerebral blood flow and cerebral amyloid angiopathy links APOE4 to amyloid deposition, while the Abstract and Brain Lipid Metabolism section describe APOE4-associated metabolic impairments that may contribute to AD. The paper does not establish that this metabolic contribution to disease risk is independent of Aβ; the Brain Lipid Metabolism section also discusses possible interactions with Aβ. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. Alata W. Ye Y. St-Amour I. Vandal M. Calon F. (2015). Human apolipoprotein E ε4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J. Cereb. Blood Flow Metab. 35, 86– 94. 10.1038/jcbfm.2014.172 25335802 PMC4296574 · DOI
  2. Altmann A. Tian L. Henderson V. W. Greicius M. D. Alzheimer’s Disease Neuroimaging Initiative Investigators. (2014). Sex modifies the APOE-related risk of developing Alzheimer disease. Ann. Neurol. 75, 563– 573. 10.1002/ana.24135 24623176 PMC4117990 · DOI · Paper page
  3. Arbones-Mainar J. M. Johnson L. A. Torres-Perez E. Garcia A. E. Perez-Diaz S. Raber J.. (2016). Metabolic shifts toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4. Int. J. Obes. 40, 1574– 1581. 10.1038/ijo.2016.93 27163745 PMC5063049 · DOI
  4. Blass J. P. (2002). Alzheimer’s disease and Alzheimer’s dementia: distinct but overlapping entities. Neurobiol. Aging 23, 1077– 1084. 10.1016/s0197-4580(02)00036-2 12470805 · DOI
  5. Carbonell F. Zijdenbos A. P. McLaren D. G. Iturria-Medina Y. Bedell B. J. (2016). Modulation of glucose metabolism and metabolic connectivity by β-amyloid. J. Cereb. Blood Flow Metab. 36, 2058– 2071. 10.1177/0271678x16654492 27301477 PMC5363668 · DOI
  6. Celsis P. Agniel A. Cardebat D. Demonet J. F. Ousset P. J. Puel M. (1997). Age related cognitive decline: a clinical entity? A longitudinal study of cerebral blood flow and memory performance. J. Neurol. Neurosurg. Psychiatry 62, 601– 608. 10.1136/jnnp.62.6.601 9219746 PMC1074144 · DOI
  7. Chan E. S. Chen C. Cole G. M. Wong B. S. (2015). Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice. Sci. Rep. 5: 13842. 10.1038/srep13842 26346625 PMC4561911 · DOI · Paper page
  8. Chouinard-Watkins R. Rioux-Perreault C. Fortier M. Tremblay-Mercier J. Zhang Y. Lawrence P.. (2013). Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoE ε4 allele. Br. J. Nutr. 110, 1751– 1759. 10.1017/S0007114513001268 23631810 · DOI
  9. Chung C. C. Pimentel D. Jor’dan A. J. Hao Y. Milberg W. Novak V. (2015). Inflammation-associated declines in cerebral vasoreactivity and cognition in type 2 diabetes. Neurology 85, 450– 458. 10.1212/WNL.0000000000001820 26156513 PMC4534073 · DOI
  10. Cox S. R. Ritchie S. J. Dickie D. A. Pattie A. Royle N. A. Corley J.. (2017). Interaction of APOE ε4 and poor glycemic control predicts white matter hyperintensity growth from 73 to 76. Neurobiol. Aging 54, 54– 58. 10.1016/j.neurobiolaging.2017.02.014 28324763 PMC5407886 · DOI
  11. Craft S. (2009). The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 66, 300– 305. 10.1001/archneurol.2009.27 19273747 PMC2717716 · DOI · Paper page
  12. de Leon M. J. Convit A. Wolf O. T. Tarshish C. Y. DeSanti S. Rusinek H.. (2001). Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U S A 98, 10966– 10971. 10.1073/pnas.191044198 11526211 PMC58582 · DOI · Paper page
  13. Di Battista A. M. Heinsinger N. M. Rebeck G. W. (2016). Alzheimer’s disease genetic risk factor APOE-ε4 also affects normal brain function. Curr. Alzheimer Res. 13, 1200– 1207. 10.2174/1567205013666160401115127 27033053 PMC5839141 · DOI
  14. Dore G. A. Elias M. F. Robbins M. A. Elias P. K. Nagy Z. (2009). Presence of the APOE ε4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study. Diabetologia 52, 2551– 2560. 10.1007/s00125-009-1497-2 19693485 · DOI · Paper page
  15. Driscoll D. M. Getz G. S. (1984). Extrahepatic synthesis of apolipoprotein E. J. Lipid Res. 25, 1368– 1379. 6530593
  16. Dumanis S. B. DiBattista A. M. Miessau M. Moussa C. E. Rebeck G. W. (2013). APOE genotype affects the presynaptic compartment of glutamatergic nerve terminals. J. Neurochem. 124, 4– 14. 10.1111/j.1471-4159.2012.07908.x 22862561 PMC3509249 · DOI · Paper page
  17. Eichner J. E. Dunn S. T. Perveen G. Thompson D. M. Stewart K. E. Stroehla B. C. (2002). Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155, 487– 495. 10.1093/aje/155.6.487 11882522 · DOI · Paper page
  18. Filippini N. Ebmeier K. P. MacIntosh B. J. Trachtenberg A. J. Frisoni G. B. Wilcock G. K.. (2011). Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage 54, 602– 610. 10.1016/j.neuroimage.2010.08.009 20705142 · DOI
  19. Foley J. M. Salat D. H. Stricker N. H. McGlinchey R. E. Milberg W. P. Grande L. J.. (2016). Glucose dysregulation interacts with APOE-4 to potentiate temporoparietal cortical thinning. Am. J. Alzheimers Dis. Other Demen. 31, 76– 86. 10.1177/1533317515587084 26006791 PMC4913470 · DOI
  20. Fryer J. D. Simmons K. Parsadanian M. Bales K. R. Paul S. M. Sullivan P. M.. (2005). Human apolipoprotein E4 alters the amyloid-β 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25, 2803– 2810. 10.1523/JNEUROSCI.5170-04.2005 15772340 PMC6725147 · DOI · Paper page
  21. Fukuyama H. Ogawa M. Yamauchi H. Yamaguchi S. Kimura J. Yonekura Y.. (1994). Altered cerebral energy metabolism in Alzheimer’s disease: a PET study. J. Nucl. Med. 35, 1– 6. 8271029
  22. Gomar J. J. Gordon M. L. Dickinson D. Kingsley P. B. Ulug A. M. Keehlisen L.. (2014). APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain. Biol. Psychiatry 75, 686– 692. 10.1016/j.biopsych.2013.05.022 23831342 PMC3887136 · DOI
  23. Gonneaud J. Arenaza-Urquijo E. M. Fouquet M. Perrotin A. Fradin S. de La Sayette V.. (2016). Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan. Neurology 87, 1696– 1703. 10.1212/WNL.0000000000003234 27683850 · DOI
  24. Grady C. L. Haxby J. V. Schlageter N. L. Berg G. Rapoport S. I. (1986). Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology 36, 1390– 1392. 10.1212/WNL.36.10.1390 3762951 · DOI
  25. Hanson A. J. Bayer J. L. Baker L. D. Cholerton B. VanFossen B. Trittschuh E.. (2015a). Differential effects of meal challenges on cognition, metabolism, and biomarkers for apolipoprotein E ε4 carriers and adults with mild cognitive impairment. J. Alzheimers Dis. 48, 205– 218. 10.3233/JAD-150273 26401941 · DOI
  26. Hanson A. J. Craft S. Banks W. A. (2015b). The APOE genotype: modification of therapeutic responses in Alzheimer’s disease. Curr. Pharm. Des. 21, 114– 120. 10.2174/1381612820666141020164222 25330331 · DOI
  27. Haxby J. V. Grady C. L. Koss E. Horwitz B. Heston L. Schapiro M.. (1990). Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 47, 753– 760. 10.1001/archneur.1990.00530070043010 2357155 · DOI
  28. Holtzman D. M. Fagan A. M. Mackey B. Tenkova T. Sartorius L. Paul S. M.. (2000). Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model. Ann. Neurol. 47, 739– 747. 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.3.co;2-# 10852539 · DOI
  29. Hoyer S. Nitsch R. Oesterreich K. (1991). Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J. Neural Transm. Park. Dis. Dement. Sect. 3, 1– 14. 10.1007/bf02251132 1905936 · DOI
  30. Johnson L. A. Torres E. R. Impey S. Stevens J. F. Raber J. (2017a). Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome. Sci. Rep. 7: 43701. 10.1038/srep43701 28272510 PMC5341123 · DOI · Paper page
  31. Johnson L. A. Torres E. R. Weber Boutros S. Patel E. Akinyeke T. Alkayed N. J.. (2017b). Apolipoprotein E4 mediates insulin resistance-associated cerebrovascular dysfunction and the post-prandial response. J. Cereb. Blood Flow Metab. [Epub ahead of print]. 10.1177/0271678x17746186 29215310 PMC6498752 · DOI · Paper page
  32. Kantarci K. Jack C. R. Jr. Xu Y. C. Campeau N. G. O’Brien P. C. Smith G. E.. (2000). Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H MRS study. Neurology 55, 210– 217. 10.1212/wnl.55.2.210 10908893 PMC2771162 · DOI
  33. Keeney J. T. Ibrahimi S. Zhao L. (2015). Human ApoE isoforms differentially modulate glucose and amyloid metabolic pathways in female brain: evidence of the mechanism of neuroprotection by apoE2 and implications for Alzheimer’s disease prevention and early intervention. J. Alzheimers Dis. 48, 411– 424. 10.3233/JAD-150348 26402005 PMC5485924 · DOI · Paper page
  34. Koehler R. C. Roman R. J. Harder D. R. (2009). Astrocytes and the regulation of cerebral blood flow. Trends Neurosci. 32, 160– 169. 10.1016/j.tins.2008.11.005 19162338 · DOI
  35. Laforce R. Jr. Rabinovici G. D. (2011). Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res. Ther. 3: 31. 10.1186/alzrt93 22071129 PMC3308020 · DOI · Paper page
  36. Lazar A. N. Bich C. Panchal M. Desbenoit N. Petit V. W. Touboul D.. (2013). Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 125, 133– 144. 10.1007/s00401-012-1041-1 22956244 · DOI
  37. Lin A. L. Jahrling J. B. Zhang W. DeRosa N. Bakshi V. Romero P.. (2017). Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. J. Cereb. Blood Flow Metab. 37, 217– 226. 10.1177/0271678x15621575 26721390 PMC5167110 · DOI
  38. Lying-Tunell U. Lindblad B. S. Malmlund H. O. Persson B. (1981). Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol. Scand. 63, 337– 350. 10.1111/j.1600-0404.1981.tb00788.x 7324866 · DOI
  39. Mahley R. W. Rall S. C. Jr. (2000). Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1, 507– 537. 10.1146/annurev.genom.1.1.507 11701639 · DOI · Paper page
  40. Morris J. K. Vidoni E. D. Wilkins H. M. Archer A. E. Burns N. C. Karcher R. T.. (2016). Impaired fasting glucose is associated with increased regional cerebral amyloid. Neurobiol. Aging 44, 138– 142. 10.1016/j.neurobiolaging.2016.04.017 27318141 PMC4913037 · DOI
  41. Mosconi L. (2013). Glucose metabolism in normal aging and Alzheimer’s disease: methodological and physiological considerations for PET studies. Clin. Transl. Imaging 1, 217– 233. 10.1007/s40336-013-0026-y 24409422 PMC3881550 · DOI · Paper page
  42. Mosconi L. De Santi S. Li J. Tsui W. H. Li Y. Boppana M.. (2008). Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 29, 676– 692. 10.1016/j.neurobiolaging.2006.12.008 17222480 PMC2430185 · DOI · Paper page
  43. Narayan K. M. Boyle J. P. Geiss L. S. Saaddine J. B. Thompson T. J. (2006). Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care 29, 2114– 2116. 10.2337/dc06-1136 16936162 · DOI · Paper page
  44. Nielsen H. M. Chen K. Lee W. Chen Y. Bauer R. J. III. Reiman E.. (2017). Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimers Res. Ther. 9: 5. 10.1186/s13195-016-0231-9 28137305 PMC5282900 · DOI
  45. Nuriel T. Angulo S. L. Khan U. Ashok A. Chen Q. Figueroa H. Y.. (2017). Neuronal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer’s disease-like pathology. Nat. Commun. 8: 1464. 10.1038/s41467-017-01444-0 29133888 PMC5684208 · DOI · Paper page
  46. Ong Q. R. Chan E. S. Lim M. L. Cole G. M. Wong B. S. (2014). Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Sci. Rep. 4: 3754. 10.1038/srep03754 24435134 PMC3894554 · DOI · Paper page
  47. Pallas F. Larson D. F. (1996). Cerebral blood flow in the diabetic patient. Perfusion 11, 363– 370. 10.1177/026765919601100502 8888057 · DOI
  48. Panchal M. Loeper J. Cossec J. C. Perruchini C. Lazar A. Pompon D.. (2010). Enrichment of cholesterol in microdissected Alzheimer’s disease senile plaques as assessed by mass spectrometry. J. Lipid Res. 51, 598– 605. 10.1194/jlr.M001859 19779135 PMC2817589 · DOI
  49. Pendse A. A. Arbones-Mainar J. M. Johnson L. A. Altenburg M. K. Maeda N. (2009). Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J. Lipid Res. 50, S178– S182. 10.1194/jlr.r800070-jlr200 19060252 PMC2674752 · DOI · Paper page
  50. Perkins M. Wolf A. B. Chavira B. Shonebarger D. Meckel J. P. Leung L.. (2016). Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E ε4 carriers. J. Alzheimers Dis. 53, 95– 106. 10.3233/JAD-151205 27128370 PMC4942726 · DOI
  51. Phelps M. E. Huang S. C. Hoffman E. J. Selin C. Sokoloff L. Kuhl D. E. (1979). Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann. Neurol. 6, 371– 388. 10.1002/ana.410060502 117743 · DOI
  52. Raber J. Huang Y. Ashford J. W. (2004). ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641– 650. 10.1016/j.neurobiolaging.2003.12.023 15172743 · DOI · Paper page
  53. Rannikmae K. Kalaria R. N. Greenberg S. M. Chui H. C. Schmitt F. A. Samarasekera N.. (2014). APOE associations with severe CAA-associated vasculopathic changes: collaborative meta-analysis. J. Neurol. Neurosurg. Psychiatry 85, 300– 305. 10.1136/jnnp-2013-306485 24163429 PMC4018226 · DOI
  54. Reger M. A. Watson G. S. Frey W. H. II. Baker L. D. Cholerton B. Keeling M. L.. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27, 451– 458. 10.1016/j.neurobiolaging.2005.03.016 15964100 · DOI
  55. Reiman E. M. Caselli R. J. Chen K. Alexander G. E. Bandy D. Frost J. (2001). Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 98, 3334– 3339. 10.1073/pnas.061509598 11248079 PMC30654 · DOI · Paper page
  56. Reiman E. M. Caselli R. J. Yun L. S. Chen K. Bandy D. Minoshima S.. (1996). Preclinical evidence of Alzheimer’s disease in persons homozygous for the ε4 allele for apolipoprotein E. N. Engl. J. Med. 334, 752– 758. 10.1056/nejm199603213341202 8592548 · DOI · Paper page
  57. Reiman E. M. Chen K. Alexander G. E. Caselli R. J. Bandy D. Osborne D.. (2004). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl. Acad. Sci. U S A 101, 284– 289. 10.1073/pnas.2635903100 14688411 PMC314177 · DOI · Paper page
  58. Reivich M. Jehle J. Sokoloff L. Kety S. S. (1969). Measurement of regional cerebral blood flow with antipyrine-14C in awake cats. J. Appl. Physiol. 27, 296– 300. 10.1152/jappl.1969.27.2.296 5796327 · DOI
  59. Riese F. Gietl A. Zölch N. Henning A. O’Gorman R. Kalin A. M.. (2015). Posterior cingulate γ-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype. Neurobiol. Aging 36, 53– 59. 10.1016/j.neurobiolaging.2014.07.030 25169676 PMC5531169 · DOI
  60. Roher A. E. Debbins J. P. Malek-Ahmadi M. Chen K. Pipe J. G. Maze S.. (2012). Cerebral blood flow in Alzheimer’s disease. Vasc. Health Risk Manag. 8, 599– 611. 10.2147/VHRM.S34874 23109807 PMC3481957 · DOI
  61. Salameh T. S. Rhea E. M. Banks W. A. Hanson A. J. (2016). Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer’s disease. Exp. Biol. Med. Maywood 241, 1676– 1683. 10.1177/1535370216660770 27470930 PMC4999626 · DOI · Paper page
  62. Sanan D. A. Weisgraber K. H. Russell S. J. Mahley R. W. Huang D. Saunders A.. (1994). Apolipoprotein E associates with β amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94, 860– 869. 10.1172/jci117407 8040342 PMC296168 · DOI · Paper page
  63. Shannon B. J. Vaishnavi S. N. Vlassenko A. G. Shimony J. S. Rutlin J. Raichle M. E. (2016). Brain aerobic glycolysis and motor adaptation learning. Proc. Natl. Acad. Sci. U S A 113, E3782– E3791. 10.1073/pnas.1604977113 27217563 PMC4932971 · DOI
  64. Shokouhi S. Riddle W. R. Kang H. (2017). A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults. Clin. Interv. Aging 12, 2123– 2130. 10.2147/CIA.S150859 29276381 PMC5734228 · DOI
  65. Small G. W. Ercoli L. M. Silverman D. H. Huang S. C. Komo S. Bookheimer S. Y.. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 97, 6037– 6042. 10.1073/pnas.090106797 10811879 PMC18554 · DOI · Paper page
  66. Small G. W. Mazziotta J. C. Collins M. T. Baxter L. R. Phelps M. E. Mandelkern M. A.. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942– 947. 10.1001/jama.1995.03520360056039 7884953 · DOI · Paper page
  67. Sokoloff L. (1977). Relation between physiological function and energy metabolism in the central nervous system. J. Neurochem. 29, 13– 26. 10.1111/j.1471-4159.1977.tb03919.x 407330 · DOI · Paper page
  68. Sokoloff L. (1984). Modeling metabolic processes in the brain in vivo. Ann. Neurol. 15, S1– S11. 10.1002/ana.410150703 6611107 · DOI
  69. Sokoloff L. Reivich M. Kennedy C. Des Rosiers M. H. Patlak C. S. Pettigrew K. D.. (1977). The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28, 897– 916. 10.1111/j.1471-4159.1977.tb10649.x 864466 · DOI · Paper page
  70. Suri S. Emir U. Stagg C. J. Near J. Mekle R. Schubert F.. (2017). Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex. Neuroimage 152, 509– 516. 10.1016/j.neuroimage.2017.03.031 28323160 PMC5440729 · DOI
  71. Tai L. M. Thomas R. Marottoli F. M. Koster K. P. Kanekiyo T. Morris A. W.. (2016). The role of APOE in cerebrovascular dysfunction. Acta Neuropathol. 131, 709– 723. 10.1007/s00401-016-1547-z 26884068 PMC4837016 · DOI · Paper page
  72. Thambisetty M. Beason-Held L. An Y. Kraut M. A. Resnick S. M. (2010). APOE ε4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 67, 93– 98. 10.1001/archneurol.2009.913 20065135 PMC2856443 · DOI
  73. Vaishnavi S. N. Vlassenko A. G. Rundle M. M. Snyder A. Z. Mintun M. A. Raichle M. E. (2010). Regional aerobic glycolysis in the human brain. Proc. Natl. Acad. Sci. U S A 107, 17757– 17762. 10.1073/pnas.1010459107 20837536 PMC2955101 · DOI · Paper page
  74. Walker J. M. Harrison F. E. (2015). Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer’s disease: impacts on cognitive decline. Nutrients 7, 7332– 7357. 10.3390/nu7095341 26340637 PMC4586536 · DOI
  75. Wierenga C. E. Clark L. R. Dev S. I. Shin D. D. Jurick S. M. Rissman R. A.. (2013). Interaction of age and APOE genotype on cerebral blood flow at rest. J. Alzheimers Dis. 34, 921– 935. 10.3233/JAD-121897 23302659 PMC4124882 · DOI
  76. Wolf A. B. Caselli R. J. Reiman E. M. Valla J. (2013). APOE and neuroenergetics: an emerging paradigm in Alzheimer’s disease. Neurobiol. Aging 34, 1007– 1017. 10.1016/j.neurobiolaging.2012.10.011 23159550 PMC3545040 · DOI
  77. Xu Q. Bernardo A. Walker D. Kanegawa T. Mahley R. W. Huang Y. (2006). Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26, 4985– 4994. 10.1523/JNEUROSCI.5476-05.2006 16687490 PMC6674234 · DOI · Paper page
  78. Zechner R. Moser R. Newman T. C. Fried S. K. Breslow J. L. (1991). Apolipoprotein E gene expression in mouse 3T3–L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J. Biol. Chem. 266, 10583– 10588. 1709937
  79. Zlatar Z. Z. Wierenga C. E. Bangen K. J. Liu T. T. Jak A. J. (2014). Increased hippocampal blood flow in sedentary older adults at genetic risk for Alzheimer’s disease. J. Alzheimers Dis. 41, 809– 817. 10.3233/JAD-132252 24685629 PMC4259215 · DOI

Cited by

Sorted by citations

Authors
Brandon, J. A., Farmer, B. C., Williams, H. C., & Johnson, L. A.
Affiliations
University of Kentucky (US)
Corresponding author
Johnson, Lance A.
ORCID
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2018-06-14
Volume
10
Pages
180-180
ISSN
1663-4365 (ISSN-L)
DOI
10.3389/fnagi.2018.00180
PMC
PMC6010552
OpenAlex
W2807958953
Cited by
75
References
15
Citations by year
2026: 8 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 13 · 2020: 12 · 2019: 12 · 2018: 1
FWCI
7.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UKnowledge (University of Kentucky) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Institute on Aging (R01AG060056)
  • National Institute of General Medical Sciences (P20GM103527, P30GM127211)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
APOE ε4, Alzheimer's disease, genetic risk factors, brain glucose metabolism, brain cholesterol, fatty acids, blood-brain barrier integrity, cerebrovascular dysfunction, positron emission tomography, magnetic resonance imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review